EICHORCondition: Hepatocellular Carcinoma · Liver Cancer, Adult · Liver Neoplasm · Sponsor: Eureka Therapeutics Inc.
This is an open-label, multi-center, Phase 1/2 clinical trial evaluating the safety, tolerability, and efficacy of ECT204, an investigational ARTEMIS® T-cell therapy, in adult subjects with GPC3-positive hepatocellular carcinoma (HCC) who have experienced disease progression on, or intolerance to, prior systemic therapy.
This description comes directly from the study's public registry record.
Teresa Klask, MBA · 925-949-9314 · Teresa.Klask@eurekainc.com
Pei Wang, PhD · 510-654-7045 · Pei.Wang@eurekainc.com
Always discuss trial participation with your own doctor first.
| City of Hope | Duarte, California, United States | Recruiting |
| Kansas University Medical Center, Principal Investigator: | Westwood, Kansas, United States | Completed |
| Roswell Park Comprehensive Cancer Center | Buffalo, New York, United States | Completed |
| Montefiore Einstein Comprehensive Cancer Center | The Bronx, New York, United States | Recruiting |
| Oregon Health and Sciences University | Portland, Oregon, United States | Recruiting |
| University of Texas Southwestern, Harold C. Simmons Comprehensive Cancer Center | Dallas, Texas, United States | Recruiting |
| Fred Hutchinson Cancer Center, University of Washington | Seattle, Washington, United States | Recruiting |
| National Taiwan University Cancer Center | Taipei, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04864054